Abstract
Neuromyelitis Optica Spectrum Disorder (NMOSD) is an inflammatory disease of the central nervous system (CNS) characterized by AQP4-IgG antibodies. While its CNS effects are well-documented, the expression of Aquaporin-4 (AQP4) in the renal collecting ducts suggests potential systemic involvement. This study investigated renal impairment in AQP4 antibody-positive NMOSD patients by evaluating estimated glomerular filtration rates (eGFR). Comparing 93 NMOSD patients, 56 multiple sclerosis (MS) patients, and 100 healthy controls (HCs), researchers found that NMOSD patients exhibit mildly but significantly lower eGFR_CysC values in both acute and stable phases compared to MS patients and HCs. These findings suggest that AQP4-IgG may cause subclinical kidney damage in NMOSD patients.
Introduction
Neuromyelitis Optica Spectrum Disorder (NMOSD) is primarily recognized for its devastating impact on the optic nerves and spinal cord. However, the pathogenic AQP4-IgG antibody targets the AQP4 water channel, which is also highly expressed in the kidneys—specifically in the basolateral membrane of principal cells in the collecting ducts. While animal models have shown that AQP4 deficiency leads to urinary concentration defects, clinical evidence of renal impairment in human NMOSD patients has remained limited. This study aimed to fill that gap by assessing renal function across different disease phases.
Methods and Study Population
The researchers conducted a cross-sectional study at the Third Affiliated Hospital of Sun Yat-sen University, recruiting 249 participants between 2012 and 2017. The cohort included:
- 93 NMOSD patients (all AQP4-IgG positive).
- 56 Multiple Sclerosis (MS) patients (neurological control group).
- 100 Healthy Controls (HCs) (age- and sex-matched).
Renal function was assessed using the estimated Glomerular Filtration Rate (eGFR), calculated via three CKD-EPI equations: eGFR_Cr (creatinine-based), eGFR_CysC (Cystatin C-based), and a combined eGFR_Cr-CysC. Cystatin C is often preferred as it is less influenced by muscle mass and diet than creatinine. Multivariate linear regression was used to adjust for age, sex, disease duration, and disability (EDSS).
Key Results
The study revealed a consistent pattern of mild renal impairment specific to the NMOSD group.
Impaired eGFR in NMOSD
NMOSD patients demonstrated significantly lower eGFR_CysC values compared to both MS patients and healthy controls. This difference persisted in both the acute and stable phases of the disease. In the acute phase, the adjusted model showed a significant reduction in eGFR_CysC for NMOSD patients compared to HCs ($p=0.001$) and MS patients ($p=0.034$).
Specificity to AQP4 Pathology
Notably, there were no significant differences in eGFR between MS patients and healthy controls. This suggests that the observed renal impairment is not a general feature of neuroinflammatory disease but is specifically linked to the AQP4-antibody pathology characteristic of NMOSD.
Stable Phase Vulnerability
The study also found that NMOSD patients in the stable phase, particularly those on low-dose glucocorticoid therapy, were at higher risk. These patients were 4.68 times more likely to have an eGFR < 90 ml/min/1.73 $m^2$ (indicating mild impairment) compared to those in the acute phase. This suggests that renal function may decline over time or be affected by long-term treatment regimens.
Discussion and Clinical Implications
These findings support the hypothesis that NMOSD is a systemic condition where AQP4-IgG targets peripheral organs expressing AQP4. The use of Cystatin C proved crucial, as standard creatinine-based tests (eGFR_Cr) failed to detect these subtle differences, likely due to the confounding effects of muscle atrophy often seen in NMOSD patients with high disability scores.
While the observed renal impairment was "mild" (with most values still within the clinically normal range), it indicates a reduced "renal reserve." Clinicians should exercise caution when prescribing nephrotoxic medications to NMOSD patients and consider monitoring renal function using Cystatin C-based eGFR.
Conclusion
AQP4 antibody-positive NMOSD is associated with a mild but statistically significant reduction in renal function. Further longitudinal studies are required to determine if this subclinical impairment progresses to overt chronic kidney disease and to better understand the long-term impact of immunosuppressive therapies on renal health in this population.
Summary updated